{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:38:25Z","timestamp":1790869105597,"version":"4.1.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,12,15]],"date-time":"2009-12-15T00:00:00Z","timestamp":1260835200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1038\/nrclinonc.2009.217","type":"journal-article","created":{"date-parts":[[2009,12,15]],"date-time":"2009-12-15T09:37:49Z","timestamp":1260869869000},"page":"108-115","source":"Crossref","is-referenced-by-count":172,"title":["Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence"],"prefix":"10.1038","volume":"7","author":[{"given":"Wim P.","family":"Ceelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Flessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,15]]},"reference":[{"key":"BFnrclinonc2009217_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1098\/rstl.1744.0006","volume":"43","author":"C Warrick","year":"1744","unstructured":"Warrick, C. An improvement on the practice of tapping; whereby that operation, instead of a relief for symptoms, becomes an absolute cure for an ascites, exemplified in the case of Jane Roman; and recommended to the consideration of the Royal Society, by Christopher Warrick, of Truro, Surgeon. Philos. Trans. R. Soc. Lond. B. Biol. Sci 43, 12\u201319 (1744).","journal-title":"Philos. Trans. R. Soc. Lond. B. Biol. Sci"},{"key":"BFnrclinonc2009217_CR2","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1001\/jama.1955.02960350004002","volume":"159","author":"AS Weisberger","year":"1955","unstructured":"Weisberger, A. S., Levine, B. & Storaasli, J. P. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J. Am. Med. Assoc. 159, 1704\u20131707 (1955).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnrclinonc2009217_CR3","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick, R. L., Myers, C. E., Bungay, P. M. & DeVita, V. T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62, 1 (1978).","journal-title":"Cancer Treat. Rep."},{"key":"BFnrclinonc2009217_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1525-1438.2007.01102.x","volume":"18","author":"M Markman","year":"2008","unstructured":"Markman, M. Strategies to examine new compounds for intraperitoneal use in ovarian cancer. Int. J. Gynecol. Cancer 18, 33\u201335 (2008).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"BFnrclinonc2009217_CR5","doi-asserted-by":"publisher","first-page":"7646","DOI":"10.1158\/0008-5472.CAN-06-4353","volume":"67","author":"XF Li","year":"2007","unstructured":"Li, X. F. et al. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res. 67, 7646\u20137653 (2007).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2009217_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/02841869709001283","volume":"36","author":"A Jakobsen","year":"1997","unstructured":"Jakobsen, A. & Mortensen, L. S. On the importance of sensitivity to the dose-effect relationship in chemotherapy. Acta Oncol. 36, 375\u2013381 (1997).","journal-title":"Acta Oncol."},{"key":"BFnrclinonc2009217_CR7","first-page":"38","volume":"12","author":"DS Alberts","year":"1985","unstructured":"Alberts, D. S., Young, L., Mason, N. & Salmon, S. E. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin. Oncol. 12, 38\u201342 (1985).","journal-title":"Semin. Oncol."},{"key":"BFnrclinonc2009217_CR8","first-page":"68","volume":"48","author":"PA Andrews","year":"1988","unstructured":"Andrews, P. A., Velury, S., Mann, S. C. & Howell, S. B. Cis-Diamminedichloroplatinum(Ii) accumulation in sensitive and resistant human ovarian carcinoma sells. Cancer Res. 48, 68\u201373 (1988).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2009217_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/BF00434345","volume":"14","author":"Y Matsushima","year":"1985","unstructured":"Matsushima, Y. et al. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother. Pharmacol. 14, 104\u2013107 (1985).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFnrclinonc2009217_CR10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/089686080302300605","volume":"23","author":"M Flessner","year":"2003","unstructured":"Flessner, M., Henegar, J., Bigler, S. & Genous, L. Is the peritoneum a significant transport barrier in peritoneal dialysis? Perit. Dial. Int. 23, 542\u2013549 (2003).","journal-title":"Perit. Dial. Int."},{"key":"BFnrclinonc2009217_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00280-003-0626-8","volume":"52","author":"VD Vazquez","year":"2003","unstructured":"Vazquez, V. D., Stuart, O. A., Mohamed, F. & Sugarbaker, P. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother. Rep. 52, 108\u2013112 (2003).","journal-title":"Cancer Chemother. Rep."},{"key":"BFnrclinonc2009217_CR12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/089686080802800102","volume":"28","author":"MF Flessner","year":"2008","unstructured":"Flessner, M. F. Endothelial glycocalyx and the peritoneal barrier. Perit. Dial. Int. 28, 6\u201312 (2008).","journal-title":"Perit. Dial. Int."},{"key":"BFnrclinonc2009217_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1525-1438.2007.01099.x","volume":"18","author":"SB Howell","year":"2008","unstructured":"Howell, S. B. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int. J. Gynecol. Cancer 18, 20\u201325 (2008).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"BFnrclinonc2009217_CR14","first-page":"1","volume":"12","author":"RL Dedrick","year":"1985","unstructured":"Dedrick, R. L. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin. Oncol. 12, 1\u20136 (1985).","journal-title":"Semin. Oncol."},{"key":"BFnrclinonc2009217_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/039139888200500101","volume":"5","author":"RL Dedrick","year":"1982","unstructured":"Dedrick, R. L., Flessner, M. F., Collins, J. M. & Schultz, J. S. Is the peritoneum a membrane? Am. Soc. Artificial Intern. Organs J. 5, 1\u20135 (1982).","journal-title":"Am. Soc. Artificial Intern. Organs J."},{"key":"BFnrclinonc2009217_CR16","first-page":"R597","volume":"246","author":"MF Flessner","year":"1984","unstructured":"Flessner, M. F., Dedrick, R. L. & Schultz, J. S. A distributed model of peritoneal-plasma transport: theoretical consideratons. Am. J. Physiol. 246, R597\u2013R607 (1984).","journal-title":"Am. J. Physiol."},{"key":"BFnrclinonc2009217_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure\u2014an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806\u2013813 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc2009217_CR18","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1158\/1078-0432.CCR-04-2332","volume":"11","author":"MF Flessner","year":"2005","unstructured":"Flessner, M. F., Choi, J., Credit, K., Deverkadra, R. & Henderson, K. Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors. Clin. Cancer Res. 11, 3117\u20133125 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2009217_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1124\/mol.104.001198","volume":"66","author":"AK Holzer","year":"2004","unstructured":"Holzer, A. K. et al. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 66, 817\u2013823 (2004).","journal-title":"Mol. Pharmacol."},{"key":"BFnrclinonc2009217_CR20","doi-asserted-by":"publisher","first-page":"6744","DOI":"10.1158\/1078-0432.CCR-04-0748","volume":"10","author":"AK Holzer","year":"2004","unstructured":"Holzer, A. K., Katano, K., Clomp, L. W. J. & Howell, S. B. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin. Cancer Res. 10, 6744\u20136749 (2004).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2009217_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/BF00257130","volume":"13","author":"T Nederman","year":"1984","unstructured":"Nederman, T. & Carlsson, J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother. Pharmacol. 13, 131\u2013135 (1984).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFnrclinonc2009217_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0959-8049(97)00370-5","volume":"34","author":"PJM van de Vaart","year":"1998","unstructured":"van de Vaart, P. J. M. et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur. J. Cancer 34, 148\u2013154 (1998).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc2009217_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumors. Nat. Rev. Cancer 6, 583\u2013592 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc2009217_CR24","doi-asserted-by":"publisher","first-page":"8782","DOI":"10.1158\/1078-0432.CCR-05-1664","volume":"11","author":"AJ Primeau","year":"2005","unstructured":"Primeau, A. J., Rendon, A., Hedley, D., Lilge, L. & Tannock, I. F. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res. 11, 8782\u20138788 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2009217_CR25","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0022-3565(24)38848-2","volume":"296","author":"SH Jang","year":"2001","unstructured":"Jang, S. H., Wientjes, M. G. & Au, J. L. S. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: Effect of treatment schedule. J. Pharmacol. Exp. Ther. 296, 1035\u20131042 (2001).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrclinonc2009217_CR26","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/bjc.1996.225","volume":"73","author":"A Kondo","year":"1996","unstructured":"Kondo, A. et al. Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Br. J. Cancer 73, 1166\u20131170 (1996).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc2009217_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","volume":"244","author":"P Esquis","year":"2006","unstructured":"Esquis, P. et al. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann. Surg. 244, 106\u2013112 (2006).","journal-title":"Ann. Surg."},{"key":"BFnrclinonc2009217_CR28","first-page":"55","volume":"41","author":"RB Jones","year":"1981","unstructured":"Jones, R. B. et al. High volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res. 41, 55\u201359 (1981).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2009217_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/ncponc0568","volume":"3","author":"VT DeVita","year":"2006","unstructured":"DeVita, V. T. Let's return to the \u201cbelly bath\u201d. Nat. Clin. Pract. Oncol. 3, 405 (2006).","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"BFnrclinonc2009217_CR30","first-page":"256","volume":"40","author":"JS Spratt","year":"1980","unstructured":"Spratt, J. S., Adcock, R. A., Muskovin, M., Sherrill, W. & Mckeown, J. Clinical delivery system for intra-peritoneal hyperthermic chemotherapy. Cancer Res. 40, 256\u2013260 (1980).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2009217_CR31","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.ejca.2008.07.038","volume":"44","author":"RD Issels","year":"2008","unstructured":"Issels, R. D. Hyperthermia adds to chemotherapy. Eur. J. Cancer 44, 2546\u20132554 (2008).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc2009217_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.radonc.2008.05.015","volume":"88","author":"XR Sun","year":"2008","unstructured":"Sun, X. R. et al. Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry. Radiother. Oncol. 88, 269\u2013276 (2008).","journal-title":"Radiother. Oncol."},{"key":"BFnrclinonc2009217_CR33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/0277-5379(91)90389-U","volume":"27","author":"G Los","year":"1991","unstructured":"Los, G. et al. Optimization of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur. J. Cancer 27, 472\u2013477 (1991).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc2009217_CR34","first-page":"1252","volume":"52","author":"G Los","year":"1992","unstructured":"Los, G. et al. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res. 52, 1252\u20131258 (1992).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2009217_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/1096-9098(200102)76:2<106::AID-JSO1020>3.0.CO;2-E","volume":"76","author":"SR Pestieau","year":"2001","unstructured":"Pestieau, S. R., Belliveau, J. F., Griffin, H., Stuart, O. A. & Sugarbaker, P. H. Pharmacokinetics of intraperitoneal oxaliplatin: Experimental studies. J. Surg. Oncol. 76, 106\u2013114 (2001).","journal-title":"J. Surg. Oncol."},{"key":"BFnrclinonc2009217_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s002800050721","volume":"41","author":"P Jacquet","year":"1998","unstructured":"Jacquet, P., Averbach, A., Stuart, O. A., Chang, D. & Sugarbaker, P. H. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother. Pharmacol. 41, 147\u2013154 (1998).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFnrclinonc2009217_CR37","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1200\/JCO.2006.07.1142","volume":"24","author":"TD Yan","year":"2006","unstructured":"Yan, T. D., Black, D., Savady, R. & Sugarbaker, P. H. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J. Clin. Oncol. 24, 4011\u20134019 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009217_CR38","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1200\/JCO.1991.9.10.1801","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman, M. et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J. Clin. Oncol. 9, 1801\u20131805 (1991).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009217_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1006\/gyno.1993.1171","volume":"50","author":"M Markman","year":"1993","unstructured":"Markman, M. et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol. Oncol. 50, 100\u2013104 (1993).","journal-title":"Gynecol. Oncol."},{"key":"BFnrclinonc2009217_CR40","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1525-1438.2007.01163.x","volume":"18","author":"A Gadducci","year":"2008","unstructured":"Gadducci, A. & Conte, P. F. Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. Int. J. Gynecol. Cancer 18, 943\u2013953 (2008).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"BFnrclinonc2009217_CR41","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ygyno.2006.07.027","volume":"104","author":"MM Juretzka","year":"2007","unstructured":"Juretzka, M. M. et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol. Oncol. 104, 176\u2013180 (2007).","journal-title":"Gynecol. Oncol."},{"key":"BFnrclinonc2009217_CR42","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","volume":"13","author":"P Francis","year":"1995","unstructured":"Francis, P. et al. Phase I feasibility and pharmacological study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J. Clin. Oncol. 13, 2961\u20132967 (1995).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009217_CR43","unstructured":"US National Insitutes of Health Intraperitoneal chemotherapy for ovarian cancer. http:\/\/ctep.cancer.gov\/highlights\/docs\/clin_annc_010506.pdf (2009)."},{"key":"BFnrclinonc2009217_CR44","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/jnci\/djj443","volume":"98","author":"M Kyrgiou","year":"2006","unstructured":"Kyrgiou, M., Salanti, G., Pavlidis, N., Paraskevaidis, E. & Ioannidis, J. P. A. Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments. J. Natl Cancer Inst. 98, 1655\u20131663 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2009217_CR45","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1634\/theoncologist.2007-0224","volume":"13","author":"I Vergote","year":"2008","unstructured":"Vergote, I. et al. Intraperitoneal chemotherapy in patients with advanced ovarian cancer: The con view. Oncologist 13, 410\u2013414 (2008).","journal-title":"Oncologist"},{"key":"BFnrclinonc2009217_CR46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S1470-2045(08)70335-8","volume":"10","author":"WP Ceelen","year":"2009","unstructured":"Ceelen, W. P. & Bracke, M. E. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol. 10, 72\u201379 (2009).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2009217_CR47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1159\/000110005","volume":"53","author":"A Hribaschek","year":"2007","unstructured":"Hribaschek, A. et al. Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis. Chemotherapy 53, 410\u2013417 (2007).","journal-title":"Chemotherapy"},{"key":"BFnrclinonc2009217_CR48","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/00000658-200004000-00001","volume":"231","author":"JC Vaillant","year":"2000","unstructured":"Vaillant, J. C. et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial. Ann. Surg. 231, 449\u2013456 (2000).","journal-title":"Ann. Surg."},{"key":"BFnrclinonc2009217_CR49","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(05)70222-9","volume":"6","author":"B Nordlinger","year":"2005","unstructured":"Nordlinger, B. et al. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II\u2013III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol. 6, 459\u2013468 (2005).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2009217_CR50","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00268-007-9146-8","volume":"31","author":"E Cotte","year":"2007","unstructured":"Cotte, E. et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: Prospective study of 81 patients. World J. Surg. 31, 1813\u20131821 (2007).","journal-title":"World J. Surg."},{"key":"BFnrclinonc2009217_CR51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ygyno.2004.05.044","volume":"94","author":"KS Ryu","year":"2004","unstructured":"Ryu, K. S. et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol. Oncol. 94, 325\u2013332 (2004).","journal-title":"Gynecol. Oncol."},{"key":"BFnrclinonc2009217_CR52","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1093\/annonc\/mdm137","volume":"18","author":"L Bijelic","year":"2007","unstructured":"Bijelic, L., Jonson, A. & Sugarbaker, P. H. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann. Oncol. 18, 1943\u20131950 (2007).","journal-title":"Ann. Oncol."},{"issue":"1","key":"BFnrclinonc2009217_CR53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ygyno.2008.12.022","volume":"113","author":"Maurie Markman","year":"2009","unstructured":"Markman, M. Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: a critical need for an evidence-based evaluation. Gynecol. Oncol. (in press) doi: 10.1016\/j.ygyno.2008.12.022.","journal-title":"Gynecologic Oncology"},{"key":"BFnrclinonc2009217_CR54","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/01.pap.0000194625.05137.51","volume":"12","author":"RK Pai","year":"2005","unstructured":"Pai, R. K. & Longacre, T. A. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Adv. Anat. Pathol. 12, 291\u2013311 (2005).","journal-title":"Adv. Anat. Pathol."},{"key":"BFnrclinonc2009217_CR55","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ctrv.2006.11.001","volume":"33","author":"RM Smeenk","year":"2007","unstructured":"Smeenk, R. M., Verwaal, V. J. & Zoetmulder, F. A. N. Pseudomyxoma peritonei. Cancer Treatment Rev. 33, 138\u2013145 (2007).","journal-title":"Cancer Treatment Rev."},{"key":"BFnrclinonc2009217_CR56","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10434-999-0727-7","volume":"6","author":"PH Sugarbaker","year":"1999","unstructured":"Sugarbaker, P. H. & Chang, D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann. Surg. Oncol. 6, 727\u2013731 (1999).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrclinonc2009217_CR57","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/bjs.6235","volume":"95","author":"D Elias","year":"2008","unstructured":"Elias, D. et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br. J. Surg. 95, 1164\u20131171 (2008).","journal-title":"Br. J. Surg."},{"key":"BFnrclinonc2009217_CR58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/01.sla.0000231705.40081.1a","volume":"245","author":"RM Smeenk","year":"2007","unstructured":"Smeenk, R. M., Verwaal, V. J., Antonini, N. & Zoetmulder, F. A. N. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. 245, 104\u2013109 (2007).","journal-title":"Ann. Surg."},{"key":"BFnrclinonc2009217_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","volume":"7","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker, P. H. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 7, 69\u201376 (2006).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2009217_CR60","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/01.sla.0000152015.76731.1f","volume":"241","author":"TJ Miner","year":"2005","unstructured":"Miner, T. J. et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann. Surg. 241, 300\u2013308 (2005).","journal-title":"Ann. Surg."},{"key":"BFnrclinonc2009217_CR61","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","volume":"89","author":"DG Jayne","year":"2002","unstructured":"Jayne, D. G., Fook, S., Loi, C. & Seow-Choen, F. Peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. 89, 1545\u20131550 (2002).","journal-title":"Br. J. Surg."},{"key":"BFnrclinonc2009217_CR62","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","volume":"22","author":"O Glehen","year":"2004","unstructured":"Glehen, O. et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J. Clin. Oncol. 22, 3284\u20133292 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009217_CR63","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal, V. J., Bruin, S., Boot, H., van Slooten, G. & van Tinteren, H. 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann. Surg. Oncol. 15, 2426\u20132432 (2008).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrclinonc2009217_CR64","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal, V. J. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 21, 3737\u20133743 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009217_CR65","first-page":"49","volume":"15","author":"P Jacquet","year":"1996","unstructured":"Jacquet, P. & Sugarbaker, P. H. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J. Exp. Clin. Cancer Res. 15, 49\u201358 (1996).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"BFnrclinonc2009217_CR66","first-page":"3072","volume-title":"14th European Cancer Conference (ECCO 14)","author":"HAM Swellengrebel","year":"2007","unstructured":"Swellengrebel, H. A. M., Verwaal, V. J., Smeenk, R. M., Antonini, N. & Zoetmulder, F. A. N. Quantitative intra-operative assessment of peritoneal carcinomatosis\u2014a comparison of three prognostic tools. 14th European Cancer Conference (ECCO 14) 3072 (Pergamon-Elsevier Science Ltd, Barcelona, Spain, 2007)."},{"key":"BFnrclinonc2009217_CR67","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/annonc\/mdf034","volume":"13","author":"CH Kohne","year":"2002","unstructured":"Kohne, C. H. et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann. Oncol. 13, 308\u2013317 (2002).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2009217_CR68","volume-title":"ASCO Gastrointestinal Cancers Symposium","author":"G Folprecht","year":"2007","unstructured":"Folprecht, G. et al. Effect of systemic chemotherapy (CTx) in patients with known peritoneal carcinomatosis (PC) from colorectal cancer [abstract 294]. ASCO Gastrointestinal Cancers Symposium (2007)."},{"key":"BFnrclinonc2009217_CR69","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","volume":"27","author":"D Elias","year":"2009","unstructured":"Elias, D. et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J. Clin. Oncol. 27, 681\u2013685 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009217_CR70","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/annonc\/mdl428","volume":"18","author":"TD Yan","year":"2007","unstructured":"Yan, T. D., Welch, L., Black, D. & Sugarbaker, P. H. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann. Oncol. 18, 827\u2013834 (2007).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2009217_CR71","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1245\/s10434-007-9487-4","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan, T. D. et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann. Surg. Oncol. 14, 2702\u20132713 (2007).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrclinonc2009217_CR72","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1200\/JCO.2007.10.8167","volume":"25","author":"G Rao","year":"2007","unstructured":"Rao, G., Crispens, M. & Rothenberg, M. L. Intraperitoneal chemotherapy for ovarian cancer: Overview and perspective. J. Clin. Oncol. 25, 2867\u20132872 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009217_CR73","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ygyno.2008.11.021","volume":"112","author":"SN Chin","year":"2009","unstructured":"Chin, S. N. et al. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma. Gynecol. Oncol. 112, 450\u2013454 (2009).","journal-title":"Gynecol. Oncol."},{"key":"BFnrclinonc2009217_CR74","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejso.2005.08.009","volume":"32","author":"RM Smeenk","year":"2006","unstructured":"Smeenk, R. M., Verwaal, V. J. & Zoetmulder, F. A. N. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei\u2014a report of 103 procedures. Eur. J. Surg. Oncol. 32, 186\u2013190 (2006).","journal-title":"Eur. J. Surg. Oncol."},{"key":"BFnrclinonc2009217_CR75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/jso.20013","volume":"85","author":"VJ Verwaal","year":"2004","unstructured":"Verwaal, V. J., Van Tinteren, H., Ruth, S. V. & Zoetmulder, F. A. N. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J. Surg. Oncol. 85, 61\u201367 (2004).","journal-title":"J. Surg. Oncol."},{"key":"BFnrclinonc2009217_CR76","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1245\/s10434-007-9648-5","volume":"15","author":"WP Ceelen","year":"2008","unstructured":"Ceelen, W. P. et al. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann. Surg. Oncol. 15, 535\u2013541 (2008).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrclinonc2009217_CR77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/bjs.1800780119","volume":"78","author":"T Shimizu","year":"1991","unstructured":"Shimizu, T., Maeta, M. & Koga, S. Influence of local hyperthermia on the Healing of small intestinal anastomoses in the rat. Br. J. Surg. 78, 57\u201359 (1991).","journal-title":"Br. J. Surg."},{"key":"BFnrclinonc2009217_CR78","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00384-006-0246-y","volume":"22","author":"JOW Pelz","year":"2007","unstructured":"Pelz, J. O. W. et al. Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model. Intl J. Colorect. Dis. 22, 941\u2013947 (2007).","journal-title":"Intl J. Colorect. Dis."},{"key":"BFnrclinonc2009217_CR79","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2622::AID-CNCR28>3.0.CO;2-T","volume":"77","author":"P Jacquet","year":"1996","unstructured":"Jacquet, P. et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 77, 2622\u20132629 (1996).","journal-title":"Cancer"},{"key":"BFnrclinonc2009217_CR80","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts, D. S. et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335, 1950\u20131955 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2009217_CR81","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman, M. et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19, 1001\u20131007 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009217_CR82","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong, D. K. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34\u201343 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2009217_CR83","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1002\/1097-0142(19921215)70:12<2754::AID-CNCR2820701205>3.0.CO;2-A","volume":"70","author":"S Fujimoto","year":"1992","unstructured":"Fujimoto, S. et al. Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin C for patients with gastric cancer with peritoneal metastasis. Cancer 70, 2754\u20132760 (1992).","journal-title":"Cancer"},{"key":"BFnrclinonc2009217_CR84","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0959-8049(97)00370-5","volume":"34","author":"PJM van de Vaart","year":"1998","unstructured":"van de Vaart, P. J. M. et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur. J. Cancer 34, 148\u2013154 (1998).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc2009217_CR85","first-page":"1252","volume":"52","author":"G Los","year":"1992","unstructured":"Los, G. et al. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res. 52, 1252\u20131258 (1992).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2009217_CR86","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias, D. et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann. Oncol. 13, 267\u2013272 (2002).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2009217_CR87","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0022-3565(24)34976-6","volume":"290","author":"HJ Kuh","year":"1999","unstructured":"Kuh, H. J., Jang, S. H., Wientjes, M. G., Weaver, J. R. & Au, J. L. S. Determinants of paclitaxel penetration and accumulation in human solid tumor. J. Pharmacol. Exp. Ther. 290, 871\u2013880 (1999).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrclinonc2009217_CR88","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1158\/1078-0432.CCR-06-1735","volume":"13","author":"RJ Morgan","year":"2007","unstructured":"Morgan, R. J. et al. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin. Cancer Res. 13, 1232\u20131237 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2009217_CR89","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/0360-3016(92)90712-Q","volume":"24","author":"G Wiedemann","year":"1992","unstructured":"Wiedemann, G., Mella, O., Roszinski, S., Weiss, C. & Wagner, T. Hyperthermia enhances mitoxantrone cytotoxicity on human breast carcinoma and sarcoma xenografts in nude mice. Int. J. Radiat. Oncol. Biol. Phys. 24, 669\u2013673 (1992).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc2009217_CR90","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s002800050721","volume":"41","author":"P Jacquet","year":"1998","unstructured":"Jacquet, P., Averbach, A., Stuart, O. A., Chang, D. & Sugarbaker, P. H. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother. Pharmacol. 41, 147\u2013154 (1998).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFnrclinonc2009217_CR91","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2307\/3579034","volume":"142","author":"S Harada","year":"1995","unstructured":"Harada, S. et al. The antitumor effect of hyperthermia combined with fluorouracil and its analogues. Radiat. Res. 142, 232\u2013241 (1995).","journal-title":"Radiat. Res."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.217","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T20:36:04Z","timestamp":1739478964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,15]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["BFnrclinonc2009217"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2009.217","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,15]]}}}